Advanced therapies like CAR-T and bispecifics are reshaping oncology, but their success now depends as much on delivery as on science. This white paper explores how FDA and CMS policy changes, mounting real-world evidence, and payer pressure are accelerating a shift toward outpatient and community delivery.